EPS for Knight Therapeutics Inc. (GUD) Expected At $0.04

February 20, 2018 - By Louis Casey

 EPS for Knight Therapeutics Inc. (GUD) Expected At $0.04

Analysts expect Knight Therapeutics Inc. (TSE:GUD) to report $0.04 EPS on March, 15.They anticipate $0.02 EPS change or 33.33 % from last quarter’s $0.06 EPS. T_GUD’s profit would be $5.72 million giving it 48.25 P/E if the $0.04 EPS is correct. After having $0.03 EPS previously, Knight Therapeutics Inc.’s analysts see 33.33 % EPS growth. The stock increased 1.18% or $0.09 during the last trading session, reaching $7.72. About 94,780 shares traded. Knight Therapeutics Inc. (TSE:GUD) has 0.00% since February 20, 2017 and is . It has underperformed by 16.70% the S&P500.

Knight Therapeutics Inc. (TSE:GUD) Ratings Coverage

Among 2 analysts covering Knight Therapeutics (TSE:GUD), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Knight Therapeutics had 11 analyst reports since May 12, 2016 according to SRatingsIntel. TD Securities maintained it with “Buy” rating and $12.50 target in Friday, March 17 report.

Knight Therapeutics Inc., a specialty pharmaceutical company, engages in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices in Canada and internationally. The company has market cap of $1.10 billion. The company's commercialized products include Impavido, an alkyllysophospholipid analogue drug for the treatment of visceral and cutaneous Leishmaniasis; Movantik for the treatment of opioid induced constipation; AzaSite to treat bacterial conjunctivitis; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Flat Tummy Tea, a herbal detox tea; and FOCUSfactor, a dietary supplement. It has a 61.76 P/E ratio. The Company’s products under development comprise Probuphine to treat opioid addiction; NeurAxon family to treat acute migraine, pain, and neurological disorders; Antibe family to treat chronic pain and inflammation; Iluvien to treat diabetic macular edema; and Netildex to treat ocular inflammation.

More notable recent Knight Therapeutics Inc. (TSE:GUD) news were published by: Seekingalpha.com which released: “Knight Therapeutics (KHTRF) CEO Jonathan Ross Goodman on Q2 2017 Results …” on August 10, 2017, also Seekingalpha.com with their article: “How Many Times Can Knight Therapeutics Issue Equity?” published on September 22, 2016, Marketwired.com published: “Knight Therapeutics and SIFI SpA Announce Filing of New Drug Submission for …” on February 15, 2018. More interesting news about Knight Therapeutics Inc. (TSE:GUD) were released by: Seekingalpha.com and their article: “Knight Therapeutics’ (KHTRF) Management on Q1 2017 Results – Earnings Call …” published on May 11, 2017 as well as Seekingalpha.com‘s news article titled: “Knight Therapeutics: The Outsider CEO You’ve Never Heard Of” with publication date: November 09, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.